Boehringer Ingelheim’s Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer

• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib is superior in reducing the risk of   lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib • More patients on afatinib were free of cancer growth 18 and 24 months after the start of treatment   (27% vs 15% and 18% vs 8%, respectively) • The overall frequency of patients experiencing serious adverse events and discontinuing treatment   due to adverse events was similar in both arms
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news